| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Duquesne Family Office · Stanley Druckenmiller | $7.2M | 0.14% | 297.60K | New | Q2 2026 |
| Renaissance Technologies | $2.5M | 0.00% | 102.50K | −73% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GLUE trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 4, 2026 | Bowen MatthewOfficer | Sale at price 10.56 per share. | 13 | $137 |
| Jul 15, 2026 | Warmuth Markus M.D.Chief Executive Officer | Sale at price 23.18 per share. | 9.5K | $220.22K |
| Jul 14, 2026 | Champoux JenniferChief Operating Officer | Conversion of Exercise of derivative security at price 3.98 per share. | 4.4K | $17.32K |
| Jul 14, 2026 | Champoux JenniferChief Operating Officer | Sale at price 23.38 per share. | 4.4K | $101.73K |
| Jul 5, 2026 | Townson SharonOfficer | Conversion of Exercise of derivative security at price 6.14 per share. | 6K | $36.84K |
| Jul 5, 2026 | Townson SharonOfficer | Sale at price 23.25 - 24.13 per share. | 6K | $139.85K |
| Jun 29, 2026 | Janku FilipOfficer | Conversion of Exercise of derivative security at price 13.41 per share. | 5.4K | $72.51K |
| Jun 29, 2026 | Janku FilipOfficer | Sale at price 24.50 per share. | 5.4K | $132.47K |
| Jun 28, 2026 | Manning Anthony MDirector | Conversion of Exercise of derivative security at price 4.16 per share. | 10K | $41.60K |
| Jun 28, 2026 | Janku FilipOfficer | Conversion of Exercise of derivative security at price 7.56 per share. | 6K | $45.36K |
| Jun 28, 2026 | Manning Anthony MDirector | Sale at price 23.11 per share. | 10K | $231.10K |
| Jun 28, 2026 | Janku FilipOfficer | Sale at price 22.95 per share. | 6K | $137.70K |
| Jun 23, 2026 | Janku FilipOfficer | Conversion of Exercise of derivative security at price 7.56 per share. | 36K | $272.16K |
| Jun 23, 2026 | Janku FilipOfficer | Sale at price 20.22 - 21.42 per share. | 41.8K | $882.20K |
| Jun 22, 2026 | Townson SharonOfficer | Conversion of Exercise of derivative security at price 6.14 per share. | 3K | $18.42K |
| Jun 22, 2026 | Champoux JenniferChief Operating Officer | Conversion of Exercise of derivative security at price 3.98 per share. | 2.2K | $8.66K |
| Jun 22, 2026 | Townson SharonOfficer | Sale at price 20.00 per share. | 3K | $60.00K |
| Jun 22, 2026 | Champoux JenniferChief Operating Officer | Sale at price 20.00 per share. | 2.2K | $43.50K |
| Jun 16, 2026 | Townson SharonOfficer | Conversion of Exercise of derivative security at price 6.14 per share. | 3K | $18.42K |
| Jun 16, 2026 | Champoux JenniferChief Operating Officer | Conversion of Exercise of derivative security at price 3.98 per share. | 2.2K | $8.66K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 30.9 | -13.5 | -7.3 | 16.4 | 2.9 | 22.8 | -31.7 | -15.6 | -14.4 | -15.8 | −36.0% | ||
| 2025 | -4.0 | -17.4 | -15.6 | 5.8 | -14.9 | 7.9 | 9.8 | -3.0 | 54.4 | 73.4 | 25.8 | -3.0 | +125.9% |
| 2024 | -6.3 | 19.5 | 11.4 | -24.5 | -22.6 | -9.2 | 20.9 | 36.5 | -14.1 | 60.4 | 21.9 | -33.0 | +22.8% |
| 2023 | -2.8 | -17.8 | 28.1 | -41.7 | 62.6 | -7.2 | 3.2 | -17.0 | -18.4 | -29.0 | -8.8 | 82.3 | −25.8% |
| 2022 | -38.0 | 13.3 | -2.2 | -22.3 | -29.0 | 24.9 | -6.2 | -12.7 | 3.2 | 12.6 | -7.8 | -10.3 | −62.7% |
| 2021 | 8.0 | 45.6 | -37.6 | 5.3 | -17.3 | 5.3 | −10.0% |
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Buy / hold / sell counts